This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LeRoith, D. Search for Related Content PubMed PubMed Citation Articles by LeRoith, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB L-TYROSINE

Editorial: Insulin-Like Growth Factor I Receptor Signaling—Overlapping or Redundant Pathways?

National Institutes of Health Bethesda, Maryland 20892-1758

Address all correspondence and requests for reprints to: Derek LeRoith, M.D., Ph.D., NIH MSC 1758, Building 10, Room 8D12, 10 Center Drive, Bethesda, Maryland 20892-1758.

	Introduction

Top Introduction References

 
The insulin-like growth factor (IGF) family of ligands and receptors are members of a highly conserved growing family of insulin-related peptides and receptors that are ubiquitously expressed. The IGF family (IGF-I, IGF-II) is distinct from insulin in the existence of a large family of high-affinity binding proteins (IGFBPs). The IGFs play important roles in numerous physiological processes. These processes range from normal growth and development during the early stages of embryogenesis to the regulation of specific functions for various tissues and organs in later stages of development. The IGFs are essential for an array of diverse processes, from progression of the cell cycle, which triggers cellular proliferation, to regulation of programmed cell death (apoptosis). These growth factors also induce cellular differentiation and stimulate certain enzymatic functions in specialized tissues. In the reproductive system, IGFs augment steroidogenesis and stimulate proliferation and differentiation of bone cells, muscle cells, and cells derived from the hematopoietic and lymphoid systems, to mention just a few examples. The total concentrations of IGF-I in the circulation are closely correlated with longitudinal growth. This and other evidence suggests that during both normal and pathophysiological situations, such as dwarfism and acromegaly, circulating IGF-I regulates body growth. In addition, locally produced IGF-I mediates critical autocrine/paracrine effects on tissues. Whatever the source of the IGFs, their biological actions are predominantly mediated by the IGF-I receptor (type 1) receptor (1). While the closely related insulin receptor is capable of binding the IGFs, this interaction is of lower affinity than of insulin for its own receptor. However, under certain circumstances, the insulin receptor may also mediate some of the biological actions of the IGFs. On the other hand, the IGF-II/mannose-6-phosphate (type 2) receptor does not appear to regulate any significant signaling cascades.

Like the insulin receptor, the insulin-like growth factor I receptor (IGF-IR), is a member of the receptor tyrosine kinase family of growth factor receptors. The IGF-IR is expressed at the cell surface as a tetramer, comprised of two and two ß subunits. The subunits are primarily localized extracellularly and mediate ligand binding, whereas the two ß subunits are primarily intracellular and possess intrinsic tyrosine kinase activity. The IGF-IR binds IGF-I and IGF-II with high affinity, and insulin at a considerably lower affinity. Ligand binding to the extracellular receptor triggers autophosphorylation of the ß subunits and stimulates the tyrosine kinase activity. This sequence of events involves a conformational change in the catalytic loop domain of the tyrosine kinase region, binding of ATP to residue lys¹⁰⁰³, and phosphorylation of residues tyr¹¹³¹, tyr¹¹³⁵, and tyr¹¹³⁶. Each ß subunit then transphosphorylates the other, leading to phosphorylation of a number of other tyrosines including, but not limited to, tyr⁹⁵⁰ in the juxtamembrane region, tyr¹²⁵⁰, tyr¹²⁵¹ and tyr¹³¹⁶ in the carboxyl-terminal domain of the ß subunit. Substitution of phenylalanine for tyrosine in each of these residues has resulted in a loss of function (2, 3, 4, 5, 6, 7).

Tyrosine phosphorylation of the IGF-I receptor has two distinct, but related, outcomes. Firstly, the tyrosine kinase activity of receptor is enhanced, and secondly, the phosphorylated tyrosine residues provide docking sites for various proteins that mediate the signaling cascades emanating from the IGF-I receptor. Previous studies have indicated that the juxtamembrane region of the cytoplasmic domain of the ß-subunit binds both Shc and the various isoforms of the IRS family of proteins. Binding of IRS proteins to the IGF-I receptor occurs via the NPXpY motif, which includes tyr⁹⁵⁰ (8, 9). Both IRS proteins and Shc proteins contain SH2 domains that bind to the activated receptor. After binding to the receptor, these proteins become phosphorylated on tyrosine residues, presumably by the IGF-I receptor. Grb2 (growth factor receptor-bound protein 2), an adapter protein, binds both Shc and IRS via its SH2 domain and via its SH3 domain to mSOS (mammalian Son of Sevenless) (10). mSos is a guanine nucleotide-exchange protein that loads GTP onto the small G protein Ras, and thereby activates the Ras/Raf/MAP kinase pathway. Tyrosine-phosphorylated IRS molecules bind the regulatory subunit (p85) of phosphoinositide 3'-kinase (PI3'K) via its SH2 domain and p85 binds the catalytic subunit of PI3'K via its SH3 domain. While other substrates are currently under investigation, these two major pathways have been identified as playing important roles in IGF-IR-induced cellular proliferation and the inhibition of apoptosis. Traditionally, the Ras/Raf/MAP kinase pathway was thought to primarily mediate the cell proliferative response to growth factors such as the IGFs, whereas the PI3'kinase pathway, which activates AKT/PKB, was primarily implicated in mediating the antiapoptotic effects of the IGFs (11, 12, 13). However, recent studies have demonstrated a role for both pathways in mediating both responses.

Naturally occurring genetic mutations in the insulin receptor have been identified in patients suffering from severe insulin resistance (14). In contrast, no such mutations have been reported in the case of the IGF-IR. Thus, a number of investigators have resorted to creating amino acid substitutions in the IGF-IR to investigate the importance of the various domains in the function of the receptor. These studies have generally proven successful and have identified specific regions of the IGF-IR that play critical roles in cell proliferation or inhibition of apoptosis. Substitutions in the tyrosine kinase domain of the ATP-binding site (lys¹⁰⁰³) results in a kinase-deficient receptor. Interestingly, this mutant functions in a dominant-negative manner, whereas mutations of the triple tyrosine motif (tyr¹¹³¹, tyr¹¹³⁵ and tyr¹¹³⁶) result in a kinase-deficient, but not dominant-negative receptor (4, 5). Both mutations result in total abrogation of IGF-IR function. Substitution of phenylalanine for tyrosine at tyr⁹⁵⁰ resulted in the loss of receptor binding to Shc and IRS molecules and interfered with IGF-I-induced mitogenic signaling and inhibition of apoptosis. While the juxtamembrane region appeared to be critical for the activation of the MAP kinase and PI3'K pathways, it soon became apparent that the C-terminal domain was also important in the function of the IGF-IR. This was determined by C-terminal deletions, which severely affected the function of the receptor (15). More specific amino acid substitutions in the C-terminus were also instructive. That is, substitution at both tyr¹²⁵⁰ and tyr¹²⁵¹ inhibited cellular proliferation, whereas substitution of the distal tyrosine (tyr 1316) did not (2). Thus, it is apparent from these and other studies that the receptor has specific domains involved in its function and that these phosphotyrosines interact with both known and currently unidentified substrates.

In this issue, Baserga and colleagues present studies that have extended these findings in a very elegant manner (16). Using cells that are do not express IRS-1 or IRS-2 (32D cells originally developed by Dr. Jackie Pierce, NIH, Bethesda, MD) they have dissected the pathways involved in cell survival. Following cytokine withdrawal, 32D cells undergo apoptosis, which can be prevented by IGFs activating the IGF-IR. In the present study, the investigators have established that in the absence IRS molecules (at least IRS-1 and IRS-2 because IRS-3 and IRS-4 levels were determined), IGF-IR activation of the MAP kinase pathway persisted. This particular finding is not unexpected to the casual reader because it has been well established that the IGF-induced activation of MAP kinase pathway can be mediated through Shc. What may be less obvious, is that MAP kinase activation prevents apoptosis. While this has been previously established in another cell line (17), the present study confirms that this is likely not to occur through IRS molecules, which, in addition to activating MAP kinase, also strongly activate the PI3'K/AKT antiapoptotic pathway. While these findings are strongly confirmatory of previous data, they were extended and revealed even more exciting results. A quartet of serine quartet residues, located at 1280–1283 in the C-terminal domain of the IGF-IR, is not present in the insulin receptor. This serine quartet, along with tyr⁹⁵⁰, was shown to be critical for maximal activation of MAP kinase by IGF-I, as mutation of these two regions together, but not separately, abrogated activation of MAP kinase by IGF-I. While tyr⁹⁵⁰ has been previously shown to interact with Shc, the molecular mechanisms that serines 1280–1283 are involved in are not yet defined. 14–3-3 proteins are obvious candidates because certain isoforms activate Raf, and recently the ß isoform of 14–3-3 has been shown to bind to this region (18, 19, 20).

It is important to consider the usual caveats when interpreting the results of these studies. The response of cells to various stimuli is frequently cell-type specific and is also dependent on the specific cellular context, i.e. what other stimuli are affecting the cell at the same time. In addition, overexpression of proteins in cell lines may alter certain physiological functions. Nevertheless, these and other studies are rapidly enhancing our understanding of the structure-function relationship of the IGF-IR. Furthermore, these findings will facilitate the identification of agents that can either enhance IGF-IR function (and thereby inhibit apoptosis and stimulate cellular proliferation) or inhibit IGF-IR function, which may be helpful in adjunct therapy for some common malignancies.

Received February 3, 2000.

	References

Top Introduction References

 

1. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT 1995 Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143–163[Abstract/Free Full Text]
2. Blakesley VA, Kalebic T, Helman LJ, Stannard B, Faria TN, Roberts Jr CT, LeRoith D 1996 Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250:1251, and 1316 in the carboxy-terminus of the IGF-I receptor. Endocrinology 137:410–417
3. Hongo A, D’Ambrosio C, Miura M, Morrione A, Baserga R 1996 Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene 12:1231–1238[Medline]
4. Kato H, Faria TN, Stannard B, Roberts Jr CT, LeRoith D 1993 Role of tyrosine kinase activity in signal transduction by the insulin- like growth factor-I (IGF-I) receptor. Characterization of kinase- deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (IR-3). J Biol Chem 268:2655–2661[Abstract/Free Full Text]
5. Kato H, Faria TN, Stannard B, Roberts Jr CT, LeRoith D 1994 Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin- like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol 8:40–50[Abstract/Free Full Text]
6. Miura M, Li S, Baserga R 1995 Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res 55:663–667[Abstract/Free Full Text]
7. O’Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R, Blattler WA 1997 Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 17:427–435[Abstract]
8. Craparo A, O’Neill TJ, Gustafson TA 1995 Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor. J Biol Chem 270:15639–15643[Abstract/Free Full Text]
9. Dey BR, Frick K, Lopaczynski W, Nissley SP, Furlanetto RW 1996 Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. Mol Endocrinol 10:631–641[Abstract/Free Full Text]
10. Pruett W, Yuan Y, Rose E, Batzer AG, Harada N, Skolnik EY 1995 Association between GRB2/Sos and insulin receptor substrate 1 is not sufficient for activation of extracellular signal-regulated kinases by interleukin-4:implications for Ras activation by insulin. Mol Cell Biol 15:1778–1785[Abstract]
11. Kulik G, Klippel A, Weber MJ 1997 Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17:1595–1606[Abstract]
12. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231–241[CrossRef][Medline]
13. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME 1997 Regulation of neuronal survival by the serine-threonine protein kinase Akt [see comments]. Science 275:661–665[Abstract/Free Full Text]
14. Taylor SI, Cama A, Accili D, Barbetti F, Quon MJ, de la Luz Sierra M, Suzuki Y, Koller E, Levy-Toledano R, Wertheimer E, Moncada VY, Kadowaki H, Kadowaki T 1992 Mutations in the insulin receptor gene. Endocr Rev 13:566–595[Abstract/Free Full Text]
15. Faria TN, Blakesley VA, Kato H, Stannard B, LeRoith D, Roberts, Jr CT 1994 Role of the carboxyl-terminal domains of the insulin and insulin-like growth factor I receptors in receptor function. J Biol Chem 269:13922–13928[Abstract/Free Full Text]
16. Dews M, Prisco M, Peruzzi F, Romano G, Morrione A, Baserga R 2000 Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases. Endocrinology 141:1289–1300[Abstract/Free Full Text]
17. Parrizas M, Saltiel AR, LeRoith D 1997 Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272:154–161[Abstract/Free Full Text]
18. Craparo A, Freund R, Gustafson TA 1997 14–3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 272:11663–11669[Abstract/Free Full Text]
19. Furlanetto RW, Dey BR, Lopaczynski W, Nissley SP 1997 14–3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor. Biochem J 327:765–771
20. Kosaki A, Yamada K, Suga J, Otaka A, Kuzuya H 1998 14–3-3ß protein associates with insulin receptor substrate 1 and decreases insulin-stimulated phosphatidylinositol 3'-kinase activity in 3T3L1 adipocytes. J Biol Chem 273:940–944[Abstract/Free Full Text]

This article has been cited by other articles:

				D. J. DiGirolamo, A. Mukherjee, K. Fulzele, Y. Gan, X. Cao, S. J. Frank, and T. L. Clemens Mode of Growth Hormone Action in Osteoblasts J. Biol. Chem., October 26, 2007; 282(43): 31666 - 31674. [Abstract] [Full Text] [PDF]

				J. L. Holzman, L. Liu, B. J. Duke, A. E. Kemendy, and D. C. Eaton Transactivation of the IGF-1R by aldosterone Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1219 - F1228. [Abstract] [Full Text] [PDF]

				J. Castillo, I. Ammendrup-Johnsen, M. Codina, I. Navarro, and J. Gutierrez IGF-I and insulin receptor signal transduction in trout muscle cells Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2006; 290(6): R1683 - R1690. [Abstract] [Full Text] [PDF]

				K. A Walters, J. P Binnie, B. K Campbell, D. G Armstrong, and E. E Telfer The effects of IGF-I on bovine follicle development and IGFBP-2 expression are dose and stage dependent. Reproduction, March 1, 2006; 131(3): 515 - 523. [Abstract] [Full Text] [PDF]

				V. C. Russo, P. D. Gluckman, E. L. Feldman, and G. A. Werther The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain Endocr. Rev., December 1, 2005; 26(7): 916 - 943. [Abstract] [Full Text] [PDF]

				D. Kiepe, S. Ciarmatori, A. Hoeflich, E. Wolf, and B. Tonshoff Insulin-Like Growth Factor (IGF)-I Stimulates Cell Proliferation and Induces IGF Binding Protein (IGFBP)-3 and IGFBP-5 Gene Expression in Cultured Growth Plate Chondrocytes via Distinct Signaling Pathways Endocrinology, July 1, 2005; 146(7): 3096 - 3104. [Abstract] [Full Text] [PDF]

				Z. Meng, P. H. King, L. B. Nabors, N. L. Jackson, C.-Y. Chen, P. D. Emanuel, and S. W. Blume The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation Nucleic Acids Res., May 24, 2005; 33(9): 2962 - 2979. [Abstract] [Full Text] [PDF]

				M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells Endocrinology, February 1, 2005; 146(2): 889 - 900. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				N. Tiffin, S. Adi, D. Stokoe, N.-Y. Wu, and S. M. Rosenthal Akt Phosphorylation Is Not Sufficient for Insulin-Like Growth Factor-Stimulated Myogenin Expression but Must Be Accompanied by Down-Regulation of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Phosphorylation Endocrinology, November 1, 2004; 145(11): 4991 - 4996. [Abstract] [Full Text] [PDF]

				A. Natalicchio, L. Laviola, C. De Tullio, L. A. Renna, C. Montrone, S. Perrini, G. Valenti, G. Procino, M. Svelto, and F. Giorgino Role of the p66Shc Isoform in Insulin-like Growth Factor I Receptor Signaling through MEK/Erk and Regulation of Actin Cytoskeleton in Rat Myoblasts J. Biol. Chem., October 15, 2004; 279(42): 43900 - 43909. [Abstract] [Full Text] [PDF]

				U. Sivaprasad, J. Fleming, P. S. Verma, K. A. Hogan, G. Desury, and W. S. Cohick Stimulation of Insulin-Like Growth Factor (IGF) Binding Protein-3 Synthesis by IGF-I and Transforming Growth Factor-{alpha} Is Mediated by Both Phosphatidylinositol-3 Kinase and Mitogen-Activated Protein Kinase Pathways in Mammary Epithelial Cells Endocrinology, September 1, 2004; 145(9): 4213 - 4221. [Abstract] [Full Text] [PDF]

				L. Sun, L. Liu, X.-J. Yang, and Z. Wu Akt binds prohibitin 2 and relieves its repression of MyoD and muscle differentiation J. Cell Sci., June 15, 2004; 117(14): 3021 - 3029. [Abstract] [Full Text] [PDF]

				Y. Huang, S.-O. Kim, N. Yang, J. Jiang, and S. J. Frank Physical and Functional Interaction of Growth Hormone and Insulin-Like Growth Factor-I Signaling Elements Mol. Endocrinol., June 1, 2004; 18(6): 1471 - 1485. [Abstract] [Full Text] [PDF]

				C. C. Zhang and H. F. Lodish Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells Blood, April 1, 2004; 103(7): 2513 - 2521. [Abstract] [Full Text] [PDF]

				A. Grey, Q. Chen, X. Xu, K. Callon, and J. Cornish Parallel Phosphatidylinositol-3 Kinase and p42/44 Mitogen-Activated Protein Kinase Signaling Pathways Subserve the Mitogenic and Antiapoptotic Actions of Insulin-Like Growth Factor I in Osteoblastic Cells Endocrinology, November 1, 2003; 144(11): 4886 - 4893. [Abstract] [Full Text] [PDF]

				A. Nunez, E. Carro, and I. Torres-Aleman Insulin-Like Growth Factor I Modifies Electrophysiological Properties of Rat Brain Stem Neurons J Neurophysiol, June 1, 2003; 89(6): 3008 - 3017. [Abstract] [Full Text] [PDF]

				T.-T. Phan, I. J. Lim, B. H. Bay, R. Qi, M. T. Longaker, S.-T. Lee, and H. Huynh Role of IGF system of mitogens in the induction of fibroblast proliferation by keloid-derived keratinocytes in vitro Am J Physiol Cell Physiol, April 1, 2003; 284(4): C860 - C869. [Abstract] [Full Text] [PDF]

				M. A. Guvakova, J. C. Adams, and D. Boettiger Functional role of {alpha}-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells J. Cell Sci., November 1, 2002; 115(21): 4149 - 4165. [Abstract] [Full Text] [PDF]

				N. Akeno, J. Robins, M. Zhang, M. F. Czyzyk-Krzeska, and T. L. Clemens Induction of Vascular Endothelial Growth Factor by IGF-I in Osteoblast-Like Cells Is Mediated by the PI3K Signaling Pathway through the Hypoxia-Inducible Factor-2{alpha} Endocrinology, February 1, 2002; 143(2): 420 - 425. [Abstract] [Full Text] [PDF]

				I. Tack, S. J. Elliot, M. Potier, A. Rivera, G. E. Striker, and L. J. Striker Autocrine Activation of the IGF-I Signaling Pathway in Mesangial Cells Isolated From Diabetic NOD Mice Diabetes, January 1, 2002; 51(1): 182 - 188. [Abstract] [Full Text] [PDF]

				J. Nakae, Y. Kido, and D. Accili Distinct and Overlapping Functions of Insulin and IGF-I Receptors Endocr. Rev., December 1, 2001; 22(6): 818 - 835. [Abstract] [Full Text] [PDF]

				B. Gonzalez, S. Lamas, and E. M. Melian Cooperation between Low Density Lipoproteins and IGF-I in the Promotion of Mitogenesis in Vascular Smooth Muscle Cells Endocrinology, November 1, 2001; 142(11): 4852 - 4860. [Abstract] [Full Text] [PDF]

				J. J. Kim, B.-C. Park, Y. Kido, and D. Accili Mitogenic and Metabolic Effects of Type I IGF Receptor Overexpression in Insulin Receptor-Deficient Hepatocytes Endocrinology, August 1, 2001; 142(8): 3354 - 3360. [Abstract] [Full Text] [PDF]

				T. W. Chan, M. Pollak, and H. Huynh Inhibition of Insulin-like Growth Factor Signaling Pathways in Mammary Gland by Pure Antiestrogen ICI 182,780 Clin. Cancer Res., August 1, 2001; 7(8): 2545 - 2554. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LeRoith, D. Search for Related Content PubMed PubMed Citation Articles by LeRoith, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB L-TYROSINE